Alirocumab as add‑on to the therapy of an adolescent with heterozygous familial hypercholesterolemia, early‑onset carotid atherosclerosis, and Alport syndrome: A clinical observation
This article presents a clinical observation of a 17-year-old adolescent with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), early-onset carotid atherosclerosis (ECAS), and concomitant Alport syndrome (AS). This patient with a strong family history of premature fatal myocardial infarction demo...